| Terrell Paul Winkler, MD | |
|
4001 North Ocean Drive, Suite 203, Fort Lauderdale, FL 33308-5968 | |
| (954) 491-5511 | |
| Not Available |
| Full Name | Terrell Paul Winkler |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Location | 4001 North Ocean Drive, Fort Lauderdale, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265587232 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | ME47696 (Florida) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Terrell Paul Winkler, MD 4001 North Ocean Drive, Suite 203, Fort Lauderdale, FL 33308-5968 Ph: (954) 491-5511 | Terrell Paul Winkler, MD 4001 North Ocean Drive, Suite 203, Fort Lauderdale, FL 33308-5968 Ph: (954) 491-5511 |
News Archive
One of the biggest difficulties in treating Parkinson's disease, a progressive neurodegenerative disorder, is the understanding of when it starts.
Accretive Health, Inc., a leading provider of end-to-end revenue cycle management services for U.S. healthcare providers, today announced it has closed its previously announced initial public offering of 11,500,000 shares of its common stock at a price to the public of $12.00 per share.
The most aggressive form of pancreatic cancer - often described as one of the hardest malignancies to diagnose and treat - thrives in the presence of neighboring tumor cells undergoing a particular form of "orchestrated cell death." This is according to a major study recently published in the journal Nature.
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, today announced the launch and availability of the VITROS XT 3400 Chemistry System, which completes the company's VITROS XT Solutions, a comprehensive suite of solutions that help labs obtain consistently fast, accurate and reliable results.
Patients with advanced non–small-cell lung cancer (NSCLC) whose tumor cells contain extra copies of the epidermal growth factor receptor (EGFR) gene may be more likely to respond to the drug gefitinib (Iressa), and this high gene copy number may be an effective predictor of gefitinib efficacy, according to a new study in the May 4 issue of the Journal of the National Cancer Institute.
› Verified 9 days ago
Dr. Ernest Costantino Jr., M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 768 Middle River Dr, Fort Lauderdale, FL 33304 Phone: 954-563-5168 | |
Ronald C Sirois, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 4701 N Federal Hwy, Ste C10, Fort Lauderdale, FL 33308 Phone: 954-771-7620 Fax: 954-771-5665 | |
Dr. Kirin K. Syed, D.O Urology Medicare: Accepting Medicare Assignments Practice Location: 4725 N Federal Hwy Ste 504, Fort Lauderdale, FL 33308 Phone: 954-267-6780 | |
Eric Scott Chenven, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1200 E Broward Blvd, Fort Lauderdale, FL 33301 Phone: 954-463-6408 Fax: 954-463-1858 | |
Louis Robert Yogel, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1200 E Broward Blvd, Fort Lauderdale, FL 33301 Phone: 954-463-6408 Fax: 954-463-1858 |